Tesamorelin is a 44-amino-acid synthetic analog of human growth-hormone-releasing hormone, modified with a trans-3-hexenoyl group for enzymatic stability. It is studied for its stimulation of endogenous pulsatile growth hormone release and is supplied strictly for laboratory research use.

How does Tesamorelin work in research models?

Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, stimulating endogenous growth hormone release and downstream IGF-1 production. This is the pathway examined in its published body-composition and metabolic research.

What purity documentation ships with Tesamorelin?

Every batch ships with a lot-specific Certificate of Analysis confirming ≥ 99% purity by HPLC and molecular identity by LC-MS, plus endotoxin screening as part of the PX1 release protocol.

How should Tesamorelin be stored and reconstituted?

Store lyophilized vials at -20 °C long term. Reconstitute with bacteriostatic water added gently down the vial wall — a 5mg vial with 2.0 mL yields 2.5 mg/mL. Refrigerate reconstituted solutions at 2–8 °C.

Is Tesamorelin approved for general human use?

Tesamorelin is supplied by PX1 Research strictly as a laboratory research compound. It is not for human or veterinary administration.

Compound Monograph — PX-TESA

Tesamorelin

GHRH analog — growth-hormone-releasing hormone research

For laboratory research use only. Not for human or veterinary use.

Compound data

Compound class: Growth-hormone-releasing hormone (GHRH) analog
Structure: 44-amino-acid peptide — human GHRH(1-44) with N-terminal trans-3-hexenoyl modification
Molecular formula: C221H366N72O67S
Molar mass: ≈ 5,135.9 g/mol
CAS number: 218949-48-5
Presentation: Lyophilized powder — 5mg and 10mg vials
Purity specification: ≥ 99% by HPLC, identity confirmed by LC-MS
Half-life (published): ≈ 26–38 minutes in plasma in published pharmacokinetic work

Overview

Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone (GHRH), consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoyl group attached at the N-terminus. This modification increases resistance to enzymatic degradation by dipeptidyl peptidase-4 relative to native GHRH.

In the research literature, Tesamorelin is studied as a stimulator of endogenous pulsatile growth hormone release from the anterior pituitary, acting through the GHRH receptor. Its most cited clinical research context is the study of visceral adipose tissue endpoints in specific studied populations.

Mechanism in the research literature

GHRH receptor binding

Tesamorelin binds the GHRH receptor on somatotroph cells of the anterior pituitary, stimulating the synthesis and pulsatile release of endogenous growth hormone in published models. Unlike direct growth hormone administration studied in other protocols, the GHRH-pathway approach preserves the physiological feedback architecture of the GH/IGF-1 axis.

Downstream IGF-1 signaling

Growth hormone released through GHRH-receptor stimulation drives hepatic insulin-like growth factor 1 (IGF-1) production, which is the downstream signaling axis examined in most Tesamorelin research contexts, including body-composition and lipid-metabolism endpoints.

Enzymatic stability modification

The N-terminal trans-3-hexenoyl modification sterically hinders DPP-4 cleavage, extending plasma stability relative to unmodified GHRH — a structural feature documented in the compound's published pharmacology.

Published research summary

Randomized controlled trials published in JAMA and related journals examined Tesamorelin's effect on visceral adipose tissue endpoints in studied populations over 26-week periods.
Published pharmacokinetic work characterizes a short plasma half-life (≈ 26–38 minutes) consistent with the native GHRH signaling pattern.
Research has examined IGF-1 response curves following GHRH-analog administration in controlled study settings.
Every PX-TESA batch is released against ≥ 99% HPLC purity with LC-MS identity confirmation and lot-specific COA documentation.

Handling, reconstitution & storage

Storage (lyophilized): -20 °C long term; 2–8 °C short term; protect from light
Reconstitution: Bacteriostatic water down the vial wall; gentle swirl until dissolved
Example ratio: 5mg vial + 2.0 mL diluent = 2.5 mg/mL (10 units = 250 mcg)
Stability (reconstituted): Reference ≈ 14–28 days refrigerated at 2–8 °C with bacteriostatic water
Freeze/thaw: Avoid repeated cycling; aliquot where the protocol requires it

Frequently asked questions

Related resources

Tesamorelin product page Tesamorelin research overview Peptide reconstitution calculator

Research use only. Tesamorelin (PX-TESA) is supplied exclusively as a laboratory research compound. It is not a drug, food, or cosmetic, and it is not intended for human or veterinary administration, diagnostic use, or household use. Statements on this page summarize published scientific literature for reference purposes and do not constitute medical advice or health claims. All PX1 Research batches ship with lot-specific Certificates of Analysis confirming ≥ 99% purity by HPLC and identity by LC-MS.